Biognosys Enters Collaboration with Leading Life Science Company to Advance Next-generation Proteomics
Biognosys, an innovator and leader in next-generation proteomics technology and solutions for life sciences research, announced today that they have entered a collaboration with Evotec, a life science company that discovers, develops, and provides highly effective therapeutics for patients, to advance the adoption of next-generation proteomics in drug discovery and clinical research.
Evotec has been a long-term user of Biognosys’ software and kits within its research. The two companies are now working closely together to integrate Biognosys’ next-generation proteomics data analysis platform in drug discovery and clinical proteomics.
Under the extended partnership, Evotec will continue to utilize Spectronaut, Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics, in its research. The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types.
Additionally, Evotec is implementing Biognosys’ unique workflow for mass spectrometry facility management. This workflow combines Biognosys’ proprietary QuiC software with its patented indexed Retention Time (iRT) technology and iRT Kit to generate near real-time readouts from mass spectrometry instrument raw files for quality control.
The collaboration uniquely combines Evotec’s partnered drug discovery and development business model and focus on data-driven precision medicine, and Biognosys’ expertise and know-how in applying next-generation proteomics to transforming drug discovery and development.
Kristina Beeler, PhD, CBO of Biognosys, comments: “We are excited to deploy the power of proteomics to address some of the key challenges of drug development and work closely with Evotec to de-risk therapeutic assets early on.”
Christoph Schaab, PhD, SVP Head of Proteomics & Metabolomics at Evotec, comments: “Discovery proteomics is increasing its importance to derive functional insights in the early stages of the drug development pipeline. We are thrilled to integrate Biognosys’ proteomics data analysis expertise into Evotec’s pre-clinical and clinical development solutions for the benefit of our biopharma partners.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About Evotec
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the worldleading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005750/en/
Contact information
Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Twilio ’s Latest Report Highlights Conversational AI’s Rapid Adoption, Challenges, and Perception Gaps13.11.2025 16:00:00 EET | Press release
Twilio (NYSE: TWLO), the customer engagement platform that drives real-time, personalized experiences for today’s leading brands, today released its Inside the Conversational AI Revolution report.1 Based on a global survey of 457 business leaders and 4,800 consumers across 15 countries, the report unearths major trends related to conversational AI’s adoption, perceptions, and expectations, including a finding that 99% of organizations anticipate their conversational AI strategy will change in the next 12 months. “Businesses that want to successfully deploy conversational AI for customer service, sales, and marketing need to prioritize customer preferences in order to build long-term trust,” said Inbal Shani, chief product officer and head of R&D at Twilio. “As with any new technology, business leaders must be ready to navigate a rapidly changing technical landscape. The key capabilities to prioritize are flexibility, experimentation, and continuous monitoring of the customer experience
Safe Software Ahead of Target to Reach $250M in Revenue by 202813.11.2025 16:00:00 EET | Press release
Safe Software (Safe), the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced strong business momentum and continued progress toward its goal of reaching $250M in revenue by 2028. Building on another year of record performance, Safe Software is ahead of its target, surpassing $100M in annual revenue in FY25, representing nearly 20% year-over-year growth. “Crossing $100M is more than a financial milestone, it’s testament to the significant value FME delivers for our customers every day,” said Don Murray, CEO of Safe Software. “As we advance toward $250M, we remain committed to empowering organizations to unlock the full potential of their data through open, scalable, and intelligent solutions” The company’s employee base increased by 21.8% over the fiscal year, reflecting strategic investments in its people, culture, and innovation to meet global demand. Internally, the growing Safe Software team has embraced AI,
Doha Debates Asks: Is ‘Earned Success’ an Illusion?13.11.2025 15:55:00 EET | Press release
Can success ever be truly earned? In its latest flagship episode, Qatar Foundation’s Doha Debates brings together global thinkers and students for a thought-provoking conversation on whether hard work and talent still determine who rises, or whether “earned success” conceals deeper inequities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113305464/en/ Doha Debates brings together global thinkers and students for a thought-provoking conversation on whether hard work and talent still determine who rises, or whether “earned success” conceals deeper inequities. (Photo: AETOSWire) Daniel Markovits, Guido Calabresi Professor of Law at Yale Law School, argues that the system meant to promote fairness has instead entrenched inequality. “Meritocracy has become the principal obstacle to equality of opportunity, at least in the rich countries of the world,” he says, warning that competition built on elite education and inherited a
FlightSafety International Announces Release of Industry-Wide Airplane Standard Operating Procedures to Elevate Safety in Business Aviation13.11.2025 15:45:00 EET | Press release
FlightSafety International Inc. today announced the publication of the Airplane Standard Operating Procedures Manual, a landmark resource that establishes consistent, proven practices for business aviation operations worldwide. Developed in collaboration with the National Business Aviation Association (NBAA), aircraft manufacturers, operators, and other leading training experts, the SOPs represent years of industry partnership dedicated to advancing aviation safety. The new manual provides uniform guidance for both single- and multi-pilot operations, reflecting best practices drawn from organizations of all sizes. By promoting widespread adoption of standardized procedures, the SOPs will strengthen consistency across fleets, enhance safety in dynamic crew environments, and generate valuable data to inform future training improvements. “FlightSafety International is proud to lead this initiative and deliver a standard that reflects the input of the entire business aviation community,” s
Experian Named One of the World’s Best Workplaces™ for Second Consecutive Year13.11.2025 15:12:00 EET | Press release
Experian has once again been recognised by Fortune and Great Place to Work® as one of the World’s Best Workplaces™ 2025, marking its second consecutive year on this prestigious global list. This honor places Experian among the top 25 companies worldwide celebrated for exceptional workplace culture, inclusivity, and employee experience. These 25 global leaders were selected from organizations that participated in Great Place to Work’s employee survey process, with over 9 million responses representing more than 25 million employees worldwide. To be considered for the list, companies must have 5,000 or more global employees, be identified as outstanding global employers with recognition on at least five Best Workplaces™ Lists in Asia, Europe, Latin America, Africa, North America, or Australia in 2024 or early 2025. “This award recognizes our people-first culture and our commitment to creating an environment where everyone can thrive,” said Brian Cassin, Experian Chief Executive Officer.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom